Alpine Immune Sciences , Inc. logo

Alpine Immune Sciences , Inc.

Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN) Alpine Immune Sciences, (NASDAQ: ALPN) is a development-stage specialty pharmaceutical company, engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases.

In Apr 2017, Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Alpine Immune, a privately-held company entered into a definitive merger agreement under which Alpine merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger results in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology.

Alpine was launched in 2015, with series seed financing from Alpine BioVentures, led by Dr. Mitchell H. Gold, Managing Partner, a long?time pioneer in the immuno?oncology area, and Jay Venkatesan, a veteran investor in the biotech space.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”ALPN” api=”yf” style=”font-size: 15px”]

Research Pipeline
BioStartup's Score 0 / 50


Disease Focus
Development StagePreclinical
201 Elliott Ave West, Suite 230,WA 098119
United States
Contact Number
+1 206-788-4545

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]

Alpine is developing novel protein-based immunotherapies using its proprietary variant immunoglobulin domain (vIgD_) platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpines vIgDs are developed using a unique process known as directed evolution, which can produce proteins capable of either enhancing or diminishing an immune response and thereby may apply therapeutically to both oncology and inflammatory diseases. Alpine has also developed its transmembrane immunomodulatory protein (TIP_) technology, based on the vIgD platform, to enhance engineered cellular therapies.


ALPN-202 is designed to antagonize PD-L1 and CTLA-4 while also providing CD28 costimulation. Recent literature suggests the lack of CD28 costimulatory signaling may be a principal reason why many tumors do not respond to PD-L1 or CTLA-4 blockade.

In Oct 2015, Alpine grants Kite Pharma (NASDAQ: KITE) an exclusive license to two Alpine programs from Alpines Transmembrane Immunomodulatory Protein (TIP) program. The license allows Kite to further engineer these candidates into chimeric antigen receptor (CAR-T) and T cell receptor product candidates. Under the terms, Kite make an upfront payment of $5 Mn and payments to support AIS research; alongwith pre?specified milestones upto $530 Mn plus single?digit royalty on sales and_Kite received exclusive worldwide license to develop & commercialize engineered autologous T cell therapies from the AIS platform.

In June 2016, Alpine raised $48 Mn in a series A round led by OrbiMed Advisors, with additional investment from Frazier Heathcare Partners and Alpine BioVentures.